Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,497.88 80.35 0.56%
TOPIX 1,171.17 4.58 0.39%
HANG SENG 22,760.24 64.23 0.28%

ABRAXANE® Extends Survival By Nearly Two Months For Patients With Advanced Pancreatic Cancer



  ABRAXANE® Extends Survival By Nearly Two Months For Patients With Advanced
                              Pancreatic Cancer

PR Newswire

MANHATTAN BEACH, Calif., Jan. 22, 2013

MANHATTAN BEACH, Calif., Jan. 22, 2013 /PRNewswire/ -- The Pancreatic Cancer
Action Network is pleased to announce that today Celgene Corporation (Celgene)
reported that the combination of its chemotherapeutic drug ABRAXANE® with
gemcitabine improved overall survival in patients with metastatic pancreatic
cancer by nearly two months (8.5 months vs. 6.7 months) when compared with
gemcitabine alone. According to Celgene, this combination also demonstrated a
59 percent increase in one-year survival compared to patients receiving
gemcitabine alone.

(Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO)

"The positive results of this trial indicate another step forward in the
treatment of this insidious disease where historically few effective treatment
options have existed.  This success also illustrates that clinical trials can
give pancreatic cancer patients access to state-of-the art treatments that may
be their best option.  We are pleased that patients will have another choice
when making treatment decisions," stated Julie Fleshman, president and CEO of
the Pancreatic Cancer Action Network.  "Further, this positive news brings us
one step closer to doubling the survival rate of pancreatic cancer by 2020."

The phase III study included 861 metastatic pancreatic cancer patients from
around the world.  Celgene plans to submit their findings to the FDA for
approval of ABRAXANE in pancreatic cancer.  ABRAXANE was previously approved
for breast cancer in 2005 and in October 2012 was approved for a type of lung
cancer. It is a form of the chemotherapy drug paclitaxel that is modified by
the addition of a human protein called albumin.

The Pancreatic Cancer Action Network encourages all patients to consider
clinical trials when exploring treatment options. The organization has a
comprehensive up-to-date database of all approved pancreatic cancer-specific
clinical trials taking place nationwide and can do a customized eligibility
search for patients through our Patient and Liaison Services program.

For more information about the Pancreatic Cancer Action Network and clinical
trials visit www.pancan.org.  

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization creating
hope in a comprehensive way through research, patient support, community
outreach and advocacy for a cure. The organization is leading the way to
increase the survival rate for people diagnosed with this devastating disease
through a bold initiative — The Vision of Progress: Double the Pancreatic
Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic
cancer by intensifying our efforts to heighten awareness, raise funds for
comprehensive private research, and advocate for dedicated federal research to
advance early diagnostics, better treatments and increase chances of survival.

For information on the listed expert, click appropriate link.
Julie Fleshman
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=75525

SOURCE Pancreatic Cancer Action Network

Website: http://www.pancan.org
Contact: Jennifer Reeves Rosen, Pancreatic Cancer Action Network,
+1-310-706-3362, jrosen@pancan.org
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement